araag2/HINT huggingface dataset:
Clinical trial NCT01177800 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo, infliximab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The body weight should be less than or equal to 80 kilogram

          -  Participants who had a diagnosis of plaque-type psoriasis (scaly skin rash) greater
             than or equal to 6 months before Screening (participants with concurrent psoriatic
             arthritis [joint pain] may be enrolled)

          -  Participants who had plaque-type psoriasis covering greater than or equal to 10
             percent of total body surface area, Psoriasis Area Severity Index (PASI) score greater
             than or equal to 12 at Screening and at the Baseline

          -  Participants who are candidates for systemic treatment of psoriasis

          -  Females of childbearing potential and all men must be using adequate birth control
             measures and agree to use these measures and should not become pregnant (carrying an
             unborn baby) or plan to become pregnant up to 6 months after receiving last infusion
             of study drug

        Exclusion Criteria:

          -  Participants who have nonplaque forms of psoriasis ( for example, erythrodermic,
             guttate, or pustular), or have current drug-induced psoriasis (for example, a new
             onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel
             blockers, or lithium)

          -  Participants who are pregnant, nursing or planning to become pregnant within one year
             while enrolled in the study

          -  Participants who had previous treatment with infliximab

          -  Participants who have received agents targeted at reducing tumour necrosis factor or
             any biologic treatment within the previous 3 months

          -  Participants who have used any investigational drug within the previous 4 weeks or 5
             times the half-life of the investigational agent, whichever is longer
Clinical trial NCT00168350 (phase 3, status: completed)
Conditions: open-angle glaucoma
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: memantine
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          -  glaucoma damage on examination of visual field and optic disc

          -  good visual acuity (with glasses if needed)
Clinical trial NCT00203060 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: rasagiline mesylate, placebo
SMILES: C#CCN[C@@H]1CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Men and women with Parkinson's disease (PD) whose diagnosis is confirmed by at least two of
        the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without other
        known or suspected cause of parkinsonism.

        Subjects must be age 35 years or older.

        Subjects not taking or requiring anti-parkinsonian medications, except for
        anticholinergics.

        Exclusion Criteria:

        Subjects with unstable systemic medical problems or clinically significant malignancy, with
        particular attention to clinically significant or unstable vascular disease
Clinical trial NCT00078819 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: etanercept, placebo
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        -  Patients with plaque psoriasis

          -  Patient may not receive certain psoriasis medications during the study
Clinical trial NCT01653262 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with well-characterized Epilepsy according to the 1989 International League
             Against Epilepsy (ILAE) classification

          -  Subject with Epilepsy who the investigator expects will benefit from Levetiracetam
             (LEV) but for whom the investigator has decided to discontinue due to nonpsychotic
             behavioral side effects following the introduction of LEV

          -  Subject is currently receiving LEV at the recommended therapeutic dose (dose ranging
             from 1 g/day to 3 g/day)

          -  Subject currently treated with minimum 2 and maximum 3 Anti-Epileptic Drugs (AEDs)
             including LEV. Vagal Nerve Stimulation (VNS) is allowed and will be counted as a
             concomitant AED

          -  Female subjects without childbearing potential (postmenopausal for at least 2 years,
             bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female
             subjects with childbearing potential are eligible if they use a medically accepted
             contraceptive method

        Exclusion Criteria:

          -  Subject has a lifetime history of suicide attempt (including an actual, interrupted or
             aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a
             positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide
             Severity Rating Scale (C-SSRS) at Visit 1

          -  Subject whose seizures could not be reliably counted on a regular basis due to their
             fast and repetitive occurrence (clusters or flurries)

          -  Subject has history or presence of status epilepticus during the year preceding Visit
             1 or during Baseline

          -  Subject has history or presence of known psychogenic nonepileptic seizures

          -  Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic
             disease, and/or severe renal impairment) which impair reliable participation in the
             study or necessitate the use of medication not allowed by protocol

          -  Subject is pregnant or lactating
Clinical trial NCT00232180 (phase 3, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: eplerenone
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  History (Hx) of chronic systolic heart failure of ischemic or non-ischemic etiology of
             at least 4 weeks duration; Currently, New York Heart Association (NYHA) functional
             Class II and on optimal dose, or maximally tolerated dose of standard heart failure
             medicines (advisable to include ACE-I/ARBs; beta-blockers) and diuretics if indicated
             for fluid overload. Should have participated in the double-blind phase of the
             EMPHASIS-HF trial

        Exclusion Criteria:

          -  Severe chronic systolic heart failure symptomatic at rest despite optimal medical
             therapy; estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2.
Clinical trial NCT01599104 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: lcz696, olmesartan, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mild-to-moderate hypertension, untreated or currently taking
             antihypertensive therapy.

          -  Treated patients (using antihypertensive treatments within 4 weeks prior to Visit 1)
             must have an msSBP ≥ 150 mmHg and < 180 mmHg at the randomization visit (Visit 201)
             and msSBP ≥140 mmHg < 180 mmHg at the visit immediately proceeding Visit 201 (Visit
             102 or 103).

          -  Untreated patients (newly diagnosed with essential hypertension or having a history of
             hypertension but have not been taking any antihypertensive drugs for at least 4 weeks
             prior to Visit 1) must have an msSBP ≥ 150 mmHg and < 180 mmHg at both Visit 1 and
             Visit 201.

          -  Patients must have an absolute difference of ≤15 mmHg in msSBP between Visit 201 and
             the immediately preceding visit;

        Exclusion Criteria:

          -  Severe hypertension (msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg).

          -  History of angioedema, drug-related or otherwise, as reported by the patient.

          -  History or evidence of a secondary form of hypertension, including but not limited to
             any of the following: renal parenchymal hypertension, renovascular hypertension
             (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary
             hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease,
             and drug-induced hypertension.

          -  Patients who previously entered a LCZ696 study and had been randomized or enrolled
             into the active drug treatment epoch.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00566735 (phase 3, status: completed)
Conditions: major depression, bipolar depression, schizoaffective disorder
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, F32.A, F53.0, P91.4, Z13.31, Z13.32, F25.9, F25.0, F25.1, F25.8
Drugs: razadyne, placebo
SMILES: [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Criteria to enter the study include males and females between the ages of 18-90
             (females must be post menopausal) and a DSM-IV diagnosis of Major Depressive Disorder,
             Major Depressive Disorder with psychotic features, Bipolar Disorder, depressed type,
             or Schizoaffective Disorder, depressed type (19).

        Exclusion Criteria:

          -  DSM-IV diagnoses of dementia and its subtypes

          -  Substance use disorder (active use within the last 6 months)

          -  Organic mental disorders; seizure disorder

          -  Unstable physical disorder or physical disorder judged to significantly affect the
             central nervous system function

          -  A heart rate of <60

          -  A systolic blood pressure < 90

          -  Heart block

          -  Pre-existing sick-sinus

          -  Chronic treatment with beta blockers

          -  Any cardiac arrythmia

          -  Hypotension

          -  Coronary artery disease

          -  Liver and renal function impairment

          -  Urge incontinence, colitis Crohn's disease, GI motility disorders, asthma and COPD

          -  Treatment with anti-cholinergic and cholinomimetic medications; and

          -  Female patients who are pregnant.

          -  Additionally, women subjects must be postmenopausal, surgically sterile, or using
             prescription oral contraceptives (e.g. estrogen-progestin combinations) ,
             contraceptive implants (e.g. NorplantTM, DepoProveraTM ), or transdermally delivered
             contraceptives (Ortho EvraTM) before entry and throughout the study; and have a
             negative serum b-HCG pregnancy test at screening.

        Note: Abstinence and the use of double barrier contraceptive methods are not acceptable in
        this study.
Clinical trial NCT00089791 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: placebo, denosumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women who are 60 to 90 years of age may be eligible to participate

          -  Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5

        Exclusion Criteria:

          -  BMD T-Score at the hip or the spine of less than -4.0

          -  Patients with any severe or more than two moderate vertebral fractures on spinal x-ray
             at entry
Clinical trial NCT01497366 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: sofosbuvir, peg, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic Genotype 2 or 3 HCV-infection

          -  Naive to all HCV antiviral treatment(s)

        Exclusion Criteria:

          -  Positive test at Screening for HBsAg, anti-hepatitis B core immunoglobulin M antibody
             (anti-HBc IgM Ab), or anti-HIV Ab

          -  History of any other clinically significant chronic liver disease

          -  A history consistent with decompensated liver disease

          -  History or current evidence of psychiatric illness, immunologic disorder,
             hemoglobinopathy, pulmonary or cardiac disease, seizure disorder or anticonvulsant
             use, poorly controlled diabetes, cancer, or a history of malignancy, that makes the
             subject unsuitable for the study.

          -  Participation in a clinical study within 3 months prior to first dose
Clinical trial NCT00642460 (phase 3, status: completed)
Conditions: juvenile idiopathic arthritis
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: tocilizumab [roactemra/actemra], placebo, non-steroidal anti-inflammatory drugs (nsaids), methotrexate, corticosteroids
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 2-17 years of age

          -  Systemic juvenile idiopathic arthritis with >= 6 months persistent activity

          -  Presence of active disease (>=5 active joints, or >=2 active joints + fever +
             steroids)

          -  Inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) and
             corticosteroids due to toxicity or lack of efficacy

        Exclusion Criteria:

          -  Wheelchair-bound or bed-ridden

          -  Any other autoimmune, rheumatic disease or overlap syndrome other than systemic
             juvenile idiopathic arthritis

          -  Intravenous long-acting corticosteroids or intra-articular corticosteroids within 4
             weeks of baseline, or throughout study

          -  Disease-modifying antirheumatic drugs (DMARDs), other than methotrexate

          -  Previous treatment with tocilizumab
Clinical trial NCT01615198 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: olmesartan, placebo, lcz696
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must give written informed consent before any assessment is performed

          -  Patients with essential hypertension, untreated or currently taking antihypertensive
             therapy must have a mean sitting systolic blood pressure ≥ 150 mmHg and < 180 mmHg

          -  Patients must be able to communicate and comply with all study requirements and
             demonstrate good medication compliance

        Exclusion criteria:

          -  Patients with severe hypertension (msDBP ≥ 110 mmHg and/or msSBP ≥180 mmHg). Patients
             with history of angioedema, drug-related or otherwise

          -  Patients with history or evidence of a secondary form of hypertension

          -  Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any
             history of stroke

          -  History of myocardial infarction, coronary bypass surgery or any percutaneous coronary
             intervention (PCI) during the 12 months prior to Visit 1.

          -  Current angina pectoris requiring medication (other than patients on a stable dose of
             oral or topical nitrates).

          -  Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled and are
             not on a stable dose of antidiabetic medication

          -  Patients with previous or current diagnosis of heart failure (NYHA Class II-IV).

          -  Patients with a clinically significant valvular heart disease at the time of screening

          -  Women of child-bearing potential, who do not use adequate birth control methods Other
             protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00728416 (phase 3, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: mometasone furoate nasal spray (mfns), matching placebo nasal spray
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A subject must be 12 years of age or older, of either sex, and of any race.

          -  A subject must have at least a 2-year history of SAR which exacerbates during the
             study season.

          -  A subject must have a positive skin prick test response to an appropriate seasonal
             allergen at Visit 1.

          -  A subject must be clinically symptomatic at the Screening and Baseline Visits.

        Exclusion Criteria:

          -  A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.

          -  A subject who has had an upper respiratory tract or sinus infection that required
             antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or
             who has had a viral upper respiratory infection within 7 days prior to the Screening
             Visit.

          -  A subject who has used any drug in an investigational protocol in the 30 days prior to
             the Screening Visit.

          -  A subject who is participating in any other clinical study.

          -  A subject who is part of the staff personnel directly involved with this study.

          -  A subject who is a family member (parent, spouse, or sibling) of the investigational
             study staff.

          -  A female subject who is breast-feeding, pregnant, or intends to become pregnant.

          -  A subject previously randomized into this study.

          -  A subject who has a family member (parent, spouse, or sibling) currently enrolled in
             this study.
Clinical trial NCT01271114 (phase 3, status: terminated)
Conditions: septic shock, sepsis-associated hypotension
ICD codes: T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD
Drugs: hypertonic saline and terlipressin, normal saline and norepinephrine
SMILES: NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NC[C@H](O)C1=CC(O)=C(O)C=C1
Reason stopped: 
    low recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Criteria of SIRS: at least 2 of 4:

               -  Temperature > 38 °c or < 36 ° C

               -  More than 90 bpm heart rate

               -  Respiratory rate more than 20rpm or PaCO2 less than 32 mm Hg or patient in
                  mechanical ventilation

               -  Less than 4000/ mm³ or more than 12000/mm³, or more than 10% leukocyte bands
                  (immature)

          -  Septic source known demonstrated (or at least of high probability) and controlled (if
             it is controllable)

          -  Hematocrit 25% or higher and/or hemoglobin 8 g/dL or higher. If necessary, transfuse
             RBCs to meet this criteria

          -  MAP less than 70 mm Hg. Note there is no requirement for adequate preload evidence

        Exclusion Criteria:

          -  Hypernatremia at base-line of 155 mEq/L or greater Hyponatremia at base-line less than
             130mEq / L

          -  Prior endocrine disease affecting to the adrenal-pituitary axis.

          -  Intracranial Hypertension, brain tumor, seizures, head trauma

          -  Coronary Artery Disease active over the past year; or evidence of "myocardium at risk"
             by exercise stress test, pharmacological or positive gammagraphy last year without
             intervention

          -  Pregnancy

          -  Liver disease Child C, End-Stage-Renal-Disease

          -  Under the age of 18

          -  Patients with order "do not resuscitate" or with minimal chances to survive
Clinical trial NCT01538225 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: sativex®, placebo
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 years or above

          -  Willing and able to comply with the protocol for the duration of the study

          -  Diagnosis of Secondary-Progressive or Primary-Progressive MS from at least 12 months

          -  Relapse free from at least 3 months before screening visit

          -  Lower limb spasticity

          -  EDSS from > 3.0 and < 6.5

          -  Moderate to severe spasticity due to MS from at least 6 months and with stable drug
             treatment not able to relieve symptoms as a whole, deserving a specific add-on
             treatment

          -  Immunomodulatory or immunosuppressant therapies not modified during the study and 6
             months before starting the study

          -  Stable doses of anti-spasticity agents from at least 2 months prior to screening visit

          -  Have given written informed consent

        Exclusion Criteria:

          -  Any concomitant disease that may cause spasticity or that could interfere with
             subject's spasticity

          -  Botulinum Toxin injection for spasticity in the 4 months prior to screening visit

          -  Any known or suspected history of psychotic illness, alcohol or substance abuse,
             epilepsy, hypersensitivity to cannabinoids

          -  Significant cardiac, renal or hepatic disease

          -  Female subjects of child bearing potentials and male subjects whose partner is child
             bearing potential, unless willing to ensure that they or their partner use
             contraception during the study

          -  Female subjects who is pregnant lactating or planning pregnancy during the course of
             the study and for three months thereafter

          -  Sativex® SmPC contraindications